Bullish & Foolish
Full INTS fundamentals All 466 on the Survival Watch

INTSINTENSITY THERAPEUTICS, INC.

Is Intensity Therapeutics struggling financially?

Yes, by its own account. Intensity Therapeutics told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$15.9M
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 6months

    If the burn speeds up

    Empty by Dec 2026

  • 9months

    If it eases off

    Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$9.5M

÷

Cash burned over the last 12 months

$15.2M

What Intensity Therapeutics told the SEC

…its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern. Note 3. Basis of Presentation and Summary of Significant Accounting Policies Basis of presentation The interim condensed financial statements included herein are unaudited. In the…

INTENSITY THERAPEUTICS, INC., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 30% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt